In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CEO Karkus Talks Cold-EEZE Turnaround At “Lean, Mean” ProPhase Labs

This article was originally published in The Tan Sheet

Executive Summary

In an interview, ProPhase Labs CEO Ted Karkus talks about the ongoing turnaround of Cold-EEZE zinc lozenges, ProPhase’s flagship brand, as well as efforts to launch new products and restore relationships with retailers.

You may also be interested in...



Matrixx Rejected On ProPhase Labs Bid, Picks Up Option On Shares

In a bid to dominate the market for zinc cold remedies, Matrixx Initiatives attempts to acquire ProPhase Labs, but is turned away by CEO Ted Karkus who asserts ProPhase’s growth prospects outweigh the benefits of a sale.

Matrixx Rejected On ProPhase Labs Bid, Picks Up Option On Shares

In a bid to dominate the market for zinc cold remedies, Matrixx Initiatives attempts to acquire ProPhase Labs, but is turned away by CEO Ted Karkus who asserts ProPhase’s growth prospects outweigh the benefits of a sale.

In Brief

Perrigo debuts Rogaine Foam equivalent; Pfizer patent suit applies heat to J&J/McNeil; Merck KGaA consumer unit beats forecast; Abbott seeks expanded vitamin D3 use; Hi-Tech Pharmacal adds to homeopathics portfolio; more news In Brief.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105485

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel